Market Highlights

Growth Hormone Deficiency (GHD) is a rare type of disorder where the pituitary gland produces an insufficient secretion of growth hormone in the body. GHD can be congenital or developed in a later stage.

Global Growth Hormone Deficiency Market is expected to have a market value of USD 5,243.3 Million by 2027.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Growth Hormone Deficiency Market— Novo Nordisk A/S, Eli Lily and Company, Novartis AG, and Merck KGaA, and Pfizer.

Regional Analysis

Global Growth Hormone Deficiency Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Rest of the World.

The Americas is classified into North America. North America is further categorized into the US Canada and Latin America. The growth hormone deficiency market in the US is expected to hold a major share owing to the growing prevalence of growth hormone deficiency and Turner syndrome, affordability of costly hormonal therapy, and the presence of a well-established healthcare sector.

The European growth hormone deficiency market is categorized into Germany, the UK, France, Italy, Spain, and the rest of Europe. The European market is expected to be the second-largest growth hormone deficiency market. This is attributed to the rising occurrences of growth hormone deficiencies, increasing preference for growth hormones in the treatment of Idiopathic Short Stature (ISS), and rising government expenditure for the healthcare sector. According to the data suggested by the Eurostat, it is observed that among the EU member states, healthcare expenditure in France and Germany was equivalent to 11.3% of the GDP in 2017, a larger share than any other EU member state. The next highest ratio was of Sweden (11.0%).

Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and the presence of a large patient pool. Growing investments in the region due to increasing demand are expected to contribute to the market growth. For instance, in March 2017, Novo Nordisk initiated a phase 3 clinical trial of somapacitan (NNC0195-0092) for Adult Growth Hormone Deficiency (AGHD) in Japan. Additionally, the rising awareness about the efficiency of growth hormone therapy in short stature is likely to increase the demand for growth hormone products in this region.

Key Findings of the Study

• Global Growth Hormone Deficiency Market is estimated to reach USD 5,243.3 Million by 2027 at a CAGR of 4.2% during the assessment period of 2020 to 2027.
• The US accounted for the largest share of the global growth hormone deficiency market due to high uptake rate, the presence of prominent players in the US, and product clearances from regulatory authorities.
• Based on brand, the norditropin segment accounted for the largest market share of 32.33% in 2019.
• On the basis of Application, the pediatric growth hormone deficiency, turner syndrome segment is expected to be the fastest-growing segment during the forecast period at a CAGR of 4.47%.
• Based on Route of Administration, the subcutaneous segment dominated the market with a share of 43.8% in the year 2019.
• Based on Distribution Channel, hospital pharmacies held the largest market share of 40.8% and the e-commerce website segment was the fastest-growing segment with a CAGR of 4.51%